jane-kelly-shutterstock-com
JANE KELLY / SHUTTERSTOCK.COM
2 June 2016Big PharmaJane Wainwright and Tom Harding

In or out? How UK and European politics are shaking IP all about

Political issues around the world have long played a major role in shaping all areas of law and science, and neither intellectual property nor the life sciences have been immune to this. There is currently, however, a heightened level of political influence on IP in Europe and in particular the UK. Significant political battles are being fought in relation to UK membership of the EU and the unitary patent system, as well as more minor lobbying in other areas such as supplementary protection certificates (SPCs).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
19 March 2026   The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.
Big Pharma
16 March 2026   Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.
Big Pharma
10 March 2026   UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.